TREE NEWS update: JD Health will sign agreements with more than 20 global pharmaceutical and health brands at the 9th China International Import Expo in Shanghai, CEO Cao Dong said, naming Pfizer, Merck, Novo Nordisk, Takeda, Boehringer Ingelheim, Haleon’s Sino-American SmithKline, Novartis and Leo Pharma among the partners. JD Health already works deeply with the world’s top 50 multinational drugmakers. In the first three quarters of 2026, the platform launched more than 100 new drugs online, exceeding all of last year.
JD Health to Sign Deals With Pfizer, Merck, 20+ Pharma Firms at CIIE
AI take
The signal here is distribution, not the signing ceremony: global drugmakers are routing new-product launches through a single Chinese online platform at scale, and the CIIE setting makes that a public, repeatable commitment rather than a one-off. The 100-plus launches in three quarters already outpacing a full prior year suggests the platform is becoming a default first-release channel for multinationals. The open question is whether that launch velocity holds as more brands onboard, and whether the CIIE deals translate into sustained listings rather than headline announcements.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
5m ago
Apple falls over 1% premarket, Meta gains narrow to 0.65%
7m ago
Lanzhou Bank Directors, Executives Raise Stake to 2.99M Shares
7m ago
Montage Technology Repurchases 336,141 A-Shares for RMB 49.75 Million
8m ago
Shanghai Stock Exchange Takes 119 Self-Regulatory Actions on Abnormal Trading
9m ago
Beijing Benz, Mercedes-Benz China recall vehicles over defect plan
10m ago
Zhengzhou Commodity Exchange sunflower oil futures and options approved for registration